New targeted pill for KRAS-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IV) or locally advanced non-squamous non-small cell lung cancer that cannot be removed with surgery or treated with radiation.
- A test shows you have the KRAS G12D mutation.
- You have not had treatment for advanced lung cancer, or you cannot receive standard treatment, or your doctor thinks the study treatment might help more.
- You must be able to provide a tumor sample (from a previous biopsy or a new one).
- You are between 18 and 75 years old.
- You are able to carry out light activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
This trial tests a new oral drug, GFH276, in people with advanced lung cancer that has a change in a gene called RAS. The drug is designed to target cancers with this specific mutation, and the study aims to find out if it is safe and effective for patients who have not had prior treatment for their advanced disease.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.